$29m market cap

$1.25 last close

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology platforms to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

Investment summary

OpGen is a diagnostic company focused on revolutionising the identification and treatment of bacterial infections. It recently merged with Curetis, a Germany-based molecular diagnostics company with a complimentary focus on infectious disease. Curetis has two main business lines: the Unyvero A50 high-plex polymerase chain reaction platform for the diagnosis of infectious disease in hospital patients, and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 2.9 (13.2) (13.4) (4445.0) N/A N/A
2019A 3.5 (11.7) (11.9) (738.0) N/A N/A
2020E 7.1 (21.4) (21.6) (139.0) N/A N/A
2021E 12.5 (17.9) (18.1) (116.0) N/A N/A
Industry outlook

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Last updated on 03/12/2019
Share price graph
Balance sheet
Forecast net debt (US$m) 28.7
Forecast gearing ratio (%) 204
Price performance
Actual 18.9 57.2 (79.6)
Relative* 16.7 87.2 (78.5)
52-week high/low US$2.2/US$0.2
*% relative to local index
Key management
Evan Jones CEO
Tim Dec CFO